Europe Balloon Aortic Valvuloplasty Market
The Europe balloon aortic valvuloplasty market was valued at US$ 50.34 million in 2023 and is expected to reach US$ 74.67 million by 2031; it is estimated to register a CAGR of 5.1% from 2023 to 2031. Improvements in TAVI Combined with Research and Development Fuel Europe Balloon Aortic Valvuloplasty Market
TAVR was originally considered only for patients with severe aortic stenosis who were considered inoperable or at very high risk. However, continuous technological evolution in valve technology and the results of randomized trials have expanded its usage to younger and lower-risk patients, making it a mainstream treatment for aortic valve disease. With developments in valve production technologies, bioprosthetic heart valves are becoming more popular and applicable to younger and lower-risk patients. With its minimally invasive feature, a majority of valve replacements will soon be via TAVR. New-generation transcatheter heart valves have substantially improved procedural efficacy, safety, and patient outcomes, making TAVR an appealing option for different patient risk groups.
Predicting the performance of the heart valve upon implantation is critically important for a successful TAVR. It is desirable to mechanically assess selected heart valves before implantation to ensure proper valve function with minimal complications after implantation. A potential practical and effective solution for applying engineering analysis to the mechanical assessment of heart valves is incorporating deep learning (DL)-based systems to advance and simplify the computational biomechanical analyses relevant to TAVR. In recent years, immense developments in DL techniques have led to state-of-the-art performances in many computer vision tasks, including image classification, image segmentation, and object detection. DL has been extensively investigated for various cardiac imaging applications, including diagnostic, prognostic, risk stratification, and therapeutic/surgical treatment planning. Numerous studies have investigated DL approaches for assessing TAVR outcomes to predict postoperative complications and prosthetic valve defects.
Through continuous research and development, the future of TAVR promises breakthrough possibilities, further strengthening its place as a transformative therapy in cardiovascular medicine. Currently, only the Edwards SAPIEN 3 Ultra, Medtronic EVOLUT FX, and Abbott Navitor valves have been approved by the FDA. Although most of the clinical experience with TAVR is linked to the Edwards and Medtronic valve systems, the potential transcatheter heart valves lineup extends beyond these leaders, with as many as five to ten new TAVR valves in the development phase. A fourth transcatheter heart valve, the Boston Scientific Acurate-neo2 valve, was approved in 2020 in Europe; in a few places, it has accomplished its randomized clinical testing with 1,500 patients across all levels of risk. A fifth valve, the JenaValve (JenaValve Technology), is approved in the EU and has an advance-device designation and an investigational device exemption from the FDA; however, this valve is being developed mainly for patients with pure aortic regurgitation.
In addition to modifications to the valves that are already available, several valves are under development by companies worldwide, and these are expected to enhance deliverability, durability, and clinical outcomes in the years to come. The future of TAVR appears bright, with indications growing, procedural volumes soaring, and an increasing number of clinical sites offering the procedure, although long-term durability remains a key concern. The leaflets of currently available valves are derived from porcine or bovine pericardial tissue. New valve platforms incorporating creative leaflet materials and other design innovations are being developed to increase long-term durability. Some new trials promise to offer crucial guidance for TAVR operators seeking to offer long-term solutions. The SMART (i.e., Small Annuli Randomized to Evolut or SAPIEN) trial is the first randomized industry-sponsored (Medtronic) head-to-head comparison of the two most commonly used TAVR devices: SAPIEN 3 and Evolut in small anatomies. The trial was conducted at 83 international sites in North America, Europe, and the Middle East & Africa. The trial enrolled 716 participants with a small aortic annulus (aortic annulus area of 430 mm2 or less based on multi-detector computed tomography) and symptomatic severe native aortic stenosis. In April 2024, the American College of Cardiology announced that findings from the SMART trial demonstrated that patients with a small aortic annulus who underwent TAVR with Evolut valve had similar clinical outcomes and superior valve performance at one year compared with patients who underwent TAVR with SAPIEN 3 valve. Researchers said the results are encouraging in terms of the clinical outcomes of both valve types. They noted that further trials could help shed light on whether TAVR offers an early advantage that is sustained with time and which of the current and upcoming transcatheter heart valves offer the best results. Researchers will continue to track outcomes over the next five years. Thus, the research and development activities focussed on improving TAVI procedures are likely to bring in new trends in the balloon aortic valvuloplasty market.Europe Balloon Aortic Valvuloplasty Market Overview
The Europe balloon aortic valvuloplasty market growth is associated with the rising prevalence of valvular diseases and the growing preference for minimally invasive surgeries. Cardiovascular diseases continue to increase and are still among the leading causes of death in Germany. The incidence of heart valve disease progresses immensely with age. Aortic stenosis is a common valvular heart disease with a dismal prognosis when untreated. TAVI or SAVR is recommended in such conditions. TAVI is a standard treatment for aortic valve stenosis in the country.
As per a study titled "Healthcare provision of transcatheter aortic valve implantation in Germany," published in 2023, a total of 26,506 TAVI procedures were performed in 2021. Compared to 2021, an increase of 4,673 TAVI procedures is to be expected by 2035. Moreover, based on a longtime voluntary registry founded by the German Society for Thoracic and Cardiovascular Surgery (GSTCVS) in 1980, well-defined data of all thoracic, cardiac, and vascular surgical procedures performed in 78 German heart surgery departments during 2022 were analyzed. A total of 93,913 heart surgical procedures were performed in 2022. Of these, 38,492 heart valve procedures were performed, including 14,852 isolated heart valve procedures performed as single, 2,880 as double, and 296 as triple valve procedures. In addition, about 20,272 transcatheter heart valve procedures were carried out. Focusing on the distribution of aortic valve procedures for 2022, 17,818 TAVI and 7,798 SAVRs were reported to the registry.
The FRANCE-TAVI Registry published an updated report of trends and evolution of TAVR in the French cohort in 2022. About 85,000 patients were enrolled, with an average age of 83 years. The number of procedures increased from 1,556 in 2010 to 14,114 in 2021. In addition, the use of TAVR was mainly restricted to those at high risk and remained uncommon in young patients in the country. According to the "Association of Age and Sex with Use of Transcatheter Aortic Valve Replacement in France," published in 2023, a total of 107,397 patients underwent an isolated aortic valve replacement (59.1% TAVR, 40.9% SAVR). In patients aged 65 years and above, the proportion of TAVR increased by 63.2% from 2015 to 2020. With a rising aging population, the prevalence of valvular heart disease is projected to surge.
The balloon aortic valvuloplasty market in the UK is likely to grow due to the rising number of people suffering from valvular diseases and the increasing geriatric population who are more susceptible to valvular diseases. According to a study published by Age UK-a registered charity in the UK-in 2020, there were nearly 12 million people aged 65 and above in the UK. It is estimated that the number of centenarians living in the UK will be 21,000 or more, and one in five people will be aged 65 and above by 2030. As per the research study titled "Uncovering the treatable burden of severe aortic stenosis in the UK," published in 2021 in the open-access journal Open Heart, ~300,000 people have aortic valve stenosis, a potentially deadly heart condition in the UK. Of the people with aortic stenosis, ~199,000 (68%) had severe aortic stenosis disease. 172,859 of these patients with severe aortic stenosis succumbed to death in 2024. The UK population's need for treatment of aortic stenosis rises as the population ages. Moreover, according to the European Heart Journal, about 1.5 million people in the UK aged 65 or over suffered from heart valve disease, including aortic stenosis, in 2015. The number is projected to double by 2046 and reach 3.3 million by 2056, which can be attributed to the aging population.
Initiatives undertaken by French government organizations to enhance awareness regarding valve replacement surgeries support market growth. The European Association of Percutaneous Cardiovascular Interventions launched the Valve for Life initiative to address the gap in heart valve disease care in Europe. It started in 2015 with the intention of addressing information gaps in heart valve care, increasing public awareness of heart valve disease, and facilitating better access to catheter-based valve interventions. The goal was to achieve a 20% improvement in the treatment of severe heart valve disease in 2020 by involving doctors, policymakers, and healthcare authorities to encourage the implementation of life-saving procedures. The program was trialed in France, Poland, and Portugal, where it led to a measurable increase in life-saving interventions for patients.
In order to raise understanding of heart valvular disease, various organizations are working toward making people more aware and funding research projects. Heart Valve Voice is a UK-dedicated heart valve disease charity. It works with patients and clinicians to improve people's awareness regarding heart valve disease and enhance diagnosis and treatment. It is a collection of people with real experiences of heart valve disease, including a multi-disciplinary group of experts in the field (cardiologists and cardiac surgeons), cardiac patient societies, and patients. Additionally, the British Heart Foundation raises funds to research cures and treatments for heart and circulatory diseases, including heart valve disease.
Europe Balloon Aortic Valvuloplasty Market Revenue and Forecast to 2031 (US$ Million)
Strategic insights for the Europe Balloon Aortic Valvuloplasty provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Europe Balloon Aortic Valvuloplasty refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
Get more information on this report Europe Balloon Aortic Valvuloplasty Strategic Insights
Get more information on this report Europe Balloon Aortic Valvuloplasty Report Scope
Report Attribute
Details
Market size in 2023
US$ 50.34 Million
Market Size by 2031
US$ 74.67 Million
Global CAGR (2023 - 2031)
5.1%
Historical Data
2025-2031
Forecast period
2021-2023
Segments Covered
By Product Type
Regions and Countries Covered
Europe
Market leaders and key company profiles
Get more information on this report Europe Balloon Aortic Valvuloplasty Regional Insights
Get more information on this report Europe Balloon Aortic Valvuloplasty Market Segmentation
The Europe balloon aortic valvuloplasty market is categorized into product type and country.
Based on product type, the Europe balloon aortic valvuloplasty market is segmented into non compliant balloons and semi compliant balloons. The non compliant balloons segment held the largest market share in 2023.
By country, the Europe balloon aortic valvuloplasty market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe balloon aortic valvuloplasty market share in 2023.
B Braun SE; TT Medical, Inc.; Balton; Becton Dickinson and Co; Edwards Lifesciences Corp; Balt; Venus MedTech HangZhou Inc; and OSYPKA are some of the leading companies operating in the Europe balloon aortic valvuloplasty market.
The Europe Balloon Aortic Valvuloplasty Market is valued at US$ 50.34 Million in 2023, it is projected to reach US$ 74.67 Million by 2031.
As per our report Europe Balloon Aortic Valvuloplasty Market, the market size is valued at US$ 50.34 Million in 2023, projecting it to reach US$ 74.67 Million by 2031. This translates to a CAGR of approximately 5.1% during the forecast period.
The Europe Balloon Aortic Valvuloplasty Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Balloon Aortic Valvuloplasty Market report:
The Europe Balloon Aortic Valvuloplasty Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Balloon Aortic Valvuloplasty Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Balloon Aortic Valvuloplasty Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Balloon Aortic Valvuloplasty Market
